Saturday 17 October 2026
Export PAVM’s income statement to Excel — free account
PAVmed Inc.
PAVM Healthcare Medical Devices
PAVmed Inc.’s revenue for fiscal 2025 (year ended December 2025) was $71,000.00, down 97.6% from fiscal 2024. In the quarter to June 2026, revenue grew 450.0%, EPS grew 96.1% and free cash flow fell 125.6%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
2.41
0.02
−0.82%
Follow PAVM
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.91 | 1.00 |
+8 more quarters Free account |
P/S ratio |
332.50 | 188.77 | 62.61 | 320.04 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(13.98) | (6.12) | (2.87) | (10.36) | |
P/B ratio |
2.41 | 0.76 | 0.00 | 0.00 | |
Price to Tangible BV |
2.57 | 0.79 | 0.00 | 0.00 | |
EV/Sales |
433.54 | 288.06 | 88.03 | 328.32 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(6.28) | (3.92) | (1.20) | (2.67) | |
EV/FCF |
(6.53) | (4.12) | (1.28) | (2.95) | |
Quick Ratio |
0.93 | 1.77 | 0.10 | 0.30 | |
Current Ratio |
1.19 | 2.02 | 0.17 | 0.40 | |
Net Debt/EBITDA |
(1.62) | (1.05) | 0.23 | 0.64 | |
Debt/Assets |
37.55% | 32.81% | 0.00% | 0.00% | |
Debt/Equity |
0.78 | 0.60 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.49 | 0.37 | 0.85 | 0.14 | |
Capex/Depreciation |
(0.68) | (1.10) | (0.78) | (0.14) | |
Interest Coverage |
(3,511.00) | (2,678.33) | (1,360.20) | (605.50) | |
Research and Development Expense of Revenue |
6,263.64% | 6,309.09% | 3,513.46% | 21,760.00% | |
Selling, General and Administrative Expense of Revenue |
14,745.45% | 29,872.73% | 9,500.00% | 74,120.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
2,778.79% | 827.27% | 446.15% | 7,660.00% | |
Graham Net Nets |
(0.43) | (0.81) | (3.14) | (1.22) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(270.18%) | (368.48%) | 109.83% | 100.04% | |
Free Cash Flow Yield |
(19.96%) | (37.03%) | (109.93%) | (34.82%) | |
Revenue per Share |
0.01 | 0.01 | 0.08 | 0.01 | |
Operating CF per Share |
(0.42) | (1.66) | (2.31) | (1.25) | |
Capex per Share |
0.00 | (0.01) | (0.02) | 0.00 | |
Free Cash Flow per Share |
(0.43) | (1.67) | (2.33) | (1.25) | |
Cash per Share |
0.60 | 4.09 | 2.29 | 4.32 | |
Shareholders Equity per Share |
3.08 | 15.81 | 33.26 | 31.38 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.08 | 15.81 | 33.26 | 31.38 | |
Free Cash Flow |
(2.68) | (2.64) | (1.56) | (0.90) | |
Working Capital |
0.77 | 3.75 | (12.28) | (6.27) | |
Capital Expenditures |
(0.01) | (0.02) | (0.01) | 0.00 | |
Net Current Asset Value |
(16.05) | (13.02) | (13.95) | (11.35) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.39 | 1.00 | 0.27 | 0.60 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.01 | 0.02 | 0.02 | 0.01 | |
Average Payables |
0.72 | 0.68 | 0.67 | 0.40 | |
Average Assets |
42.05 | 49.12 | 34.74 | 34.31 | |
Average Common Equity |
9.52 | 16.94 | (6.36) | (7.08) |
Columns are period end dates